One Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

One Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-136	Closed	-$5K	–	431
2019 Q1	$5K	Buy	+136	New	+$5.06K	﹤0.01%	372
2018 Q4	–	Sell	-78	Closed	-$4K	–	425
2018 Q3	$4K	Buy	78 +32	+70%	+$1.58K	﹤0.01%	442
2018 Q2	$3K	Sell	46 -21	-31%	-$1.09K	﹤0.01%	482
2018 Q1	$3K	Hold	67	–	–	﹤0.01%	448
2017 Q4	$3K	Buy	+67	New	+$2.65K	﹤0.01%	492

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

One Wealth Advisors's SUPN Position: Q2 2019 in Review

One Wealth Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 136 shares — an estimated $5K sold.

One Wealth Advisors first reported a position in SUPN in Q4 2017 and held it in 5 quarters. The position peaked at $5K in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

One Wealth Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
One Wealth Advisors sold 136 Supernus Pharmaceuticals shares in Q2 2019, an estimated $5K.
One Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 5 quarters.
One Wealth Advisors's Supernus Pharmaceuticals position peaked at $5K in Q1 2019.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on One Wealth Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.